INCY Company Profile and Key Details

Q: Who are the executives of INCY?

Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D.Executive Vice President & GM of North AmericaMs. Christiana Stamoulis MBAExecutive Vice President & Chief Financial OfficerMr. Herve HoppenotChief Executive Officer & ChairmanDr. Pablo J. Cagnoni M.D., Ph.D.Pres and Head of R&DMs. Christine ChiouHead of Investor RelationsDr. Dashyant Dhanak Ph.D.Executive Vice President & Chief Scientific OfficerMr. Thomas TrayVice President of Fin., Chief Accounting Officer & ControllerMs. Pamela M. MurphyVice President of Investor Relations & Corporation CommunicationsMs. Maria E. Pasquale J.D.Executive Vice President, Gen. Counsel & Corporation Sec.Ms. Maria E. PasqualeExecutive Vice President, Gen. Counsel & Corporation Sec.Dr. Steven H. Stein M.D.Executive Vice President & Chief Medical OfficerMr. Michael James MorrisseyExecutive Vice President & Head of Global Technical Operations

NASDAQ : INCY

Incyte

$106.87

0.95+0.90%

At Close 4:00 PM

52.46

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Incyte Corporation (INCY) stock surged +0.90%, trading at $106.87 on NASDAQ, up from the previous close of $105.92. The stock opened at $106.04, fluctuating between $105.93 and $107.69 in the recent session.

Stock Snapshot

105.92

Prev. Close

20.98B

Market Cap

105.9337

Day Low

18.11

P/E Ratio

5.9

EPS (TTM)

Cash Flow per Share

106.04

Open

196.32M

Number of Shares

107.685

Day High

98.8%

Free Float in %

23.15

Book Value

1.52M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 09, 2026	106.04	107.69	105.93	106.87	1.52M
Jan 08, 2026	109.74	110.09	104.69	105.92	2.58M
Jan 07, 2026	107.88	112.29	107.88	110.57	3.37M
Jan 06, 2026	101.73	107.48	101.02	106.66	3.85M
Jan 05, 2026	103.00	103.01	99.04	101.79	3.05M
Jan 02, 2026	98.25	101.50	97.94	101.42	2.15M
Dec 31, 2025	98.43	99.89	98.13	98.77	1.37M
Dec 30, 2025	99.21	99.28	98.06	98.91	1.59M
Dec 29, 2025	100.03	100.08	97.63	99.29	1.15M
Dec 26, 2025	100.41	100.41	99.57	100.11	567.59K
Dec 24, 2025	100.94	101.51	100.30	100.44	490.61K
Dec 23, 2025	100.50	101.71	100.04	100.91	1.05M
Dec 22, 2025	101.94	102.52	98.99	100.71	1.87M
Dec 19, 2025	97.77	103.45	97.36	102.69	5.89M
Dec 17, 2025	97.26	98.90	97.09	97.63	1.54M
Dec 16, 2025	98.17	98.69	96.40	97.03	2.01M
Dec 15, 2025	96.27	99.44	95.48	98.64	2.78M
Dec 12, 2025	95.76	96.00	93.54	95.41	2.16M
Dec 11, 2025	94.94	96.89	94.39	96.10	1.75M
Dec 10, 2025	95.58	96.88	94.28	95.17	1.86M

Contact Details

Wilmington, DE 19803

United States

https://www.incyte.com 302 498 6700

About Company

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Stock Peers

REGN

-4.46-0.56%

Regeneron Pharmaceuticals, Inc.$796.55 ARGX

-7.07997-0.89%

argenx SE$788.49 MDGL

-42.16-7.58%

Madrigal Pharmaceuticals, Inc.$514.06 UTHR

-7.6-1.55%

United Therapeutics Corporation$483.23 VRTX

-5.82-1.24%

Vertex Pharmaceuticals Incorporated$463.86 ALNY

-1.11-0.28%

Alnylam Pharmaceuticals, Inc.$398.29 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-5.93-2.01%

Praxis Precision Medicines, Inc.$288.45 KRYS

12.5+5.02%

Krystal Biotech, Inc.$261.41 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Incyte Corporation (NASDAQ:INCY) closed at $106.87 USD, gaining $0.95 (0.90%) from the previous close of $105.92. The stock is currently within 5% of its 52-week high $53.56 and $112.29. With a market capitalization of about $20.98 billion, Incyte Corporation is classified as a large-cap and shows market-like volatility (beta ~0.82). Key stats such as the average daily volume over the past year has been around 2.35 million shares, volume is running light vs its 52-week average. Headquartered in Wilmington, DE, Incyte Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO William Meury, the company employs approximately 2,617 people and listed since November 04, 1993. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.

Technical Performance

INCY has shown sold momentum, gaining 7.24% over the past week and 21.51% over the past quarter, though year-to-date performance is up 7.24%. Short-term trend indicators are mixed aligned (SMA20 5.96%, SMA50 5.25%, SMA200 33.13%). The stock’s 14-day RSI is 60.88 (firm momentum), while the ATR of 3.35 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -4.83% below its high and over 99.53% above its low. Average 10-day trading volume of 2.75 million shares is slightly above the 3-month average of 2.31 million, indicating heightened recent market interest.

Valuation Metrics

Incyte Corporation trades at a P/E ratio of 17.59, slightly below the S&P 500 average, with a price-to-sales ratio of 4.36 and a price-to-book ratio of 4.5 trading at moderately above to book value. The P/FCF stands at 17.53, also below market averages.

Dividend & Fair Value

Incyte Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $93.86. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Incyte Corporation generated EPS of $5.96 over the past year. Five-year average earnings growth is -40.36%. Wall Street analysts project EPS growth of 105.38% annually over the next five years. The latest quarter delivered EPS of $2.11. The next quarter is forecast at $1.93. Next year's EPS is expected at $19.49. Analyst sentiment is neutral. Analyst rating data shows there are 8 Strong Buy ratings, 6 Buy ratings, 19 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $125.00 to $60.00. The high target offers 16.96% upside. The low target suggests -43.86% downside. The mean target is $88.15. This offers -17.52% upside. Incyte Corporation earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by 27.11%. The prior quarter beat by 12.95%. Over the last six quarters, Apple has recorded several small beats. These include -275.67% in July 30, 2024.

Shareholding & Insider Activity

Incyte Corporation has 195.28 million shares outstanding. The public float is 163.04 million shares, elevated short interest at 5.37% of float. This equals 7.42 million shares. The short ratio is 4.42 days. Institutional investors hold 105.61% of the float. Insiders own 2.03%. BAKER FELIX holds 2.93 million shares, BAKER BROS. ADVISORS LP has 2.93 million shares and Hoppenot Herve has 329.65 thousand shares. Over the past six months, insider transactions show net selling. They sold 346.88 thousand shares across 32 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Incyte generated $3.70B in revenue, or $16.36 per share. Gross margin was 93.10%, operating margin 16.79%, and net profit margin 16.17%. Returns are healthy, with ROA at 8.81% and ROE at 11.51%.
On valuation metrics, Incyte trades at a P/E of 17.59, P/S of 4.36 and P/B of 4.50. The current ratio is 3.19 and quick ratio is 2.86. Operationally, the company’s inventory turnover is 0.87 and cash conversion cycle is -878.73 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of 30.32.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Incyte posted revenue of $3.70B, down slightly from $3.39B in the prior quarter. Gross profit was $3.44B (margin 93.10%). Operating income was $620.53M (margin 16.8%). Net income was$597.60M (EPS $2.67).
The company ended the quarter with $3.66B in cash and short-term investments, a total debt of $38.29M, and net debt of - $3.18B. Total assets were $6.78B, with equity of $5.19B. Financials further reflected stability, with operating cash flow of $496.49M, free cash flow of $449.00M, and capital expenditures of - $47.49M.

Price Forecast & Outlook

Our AI price prediction model suggests that Incyte Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.59%, with price expected at $112.84 by January 23, 2026, within a range of $110.01 to $115.98 3-Month Outlook: Projected rise of 8.94%, reaching $116.42 by April 09, 2026, with a range of $114.86 to $118.25. 1-Year Outlook: Projected loss of -2.9%, with price at $103.77 by December 31, 2026, within a range of $99.94 to $108.24.

Key Takeaways

Incyte Corporation (NASDAQ:INCY) shares are flat 7.24% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Incyte Corporation trading at a premium to the broader market with a P/E of 17.59. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $83.33, suggesting -22.03% downside. Our AI forecast model points to short-term strength (5.59% over two weeks), a medium-term rise (8.94% over three months), and a longer-term loss (-2.9% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Incyte Corporation (INCY) stock price?

Incyte Corporation (NASDAQ: INCY) stock price is $106.87 in the last trading session. During the trading session, INCY stock reached the peak price of $107.69 while $105.93 was the lowest point it dropped to. The percentage change in INCY stock occurred in the recent session was 0.9% while the dollar amount for the price change in INCY stock was $0.95.

INCY's industry and sector of operation?

The NASDAQ listed INCY is part of Biotechnology industry that operates in the broader Healthcare sector. Incyte Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of INCY?

Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D.
Executive Vice President & GM of North America
Ms. Christiana Stamoulis MBA
Executive Vice President & Chief Financial Officer
Mr. Herve Hoppenot
Chief Executive Officer & Chairman
Dr. Pablo J. Cagnoni M.D., Ph.D.
Pres and Head of R&D
Ms. Christine Chiou
Head of Investor Relations
Dr. Dashyant Dhanak Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. Thomas Tray
Vice President of Fin., Chief Accounting Officer & Controller
Ms. Pamela M. Murphy
Vice President of Investor Relations & Corporation Communications
Ms. Maria E. Pasquale J.D.
Executive Vice President, Gen. Counsel & Corporation Sec.
Ms. Maria E. Pasquale
Executive Vice President, Gen. Counsel & Corporation Sec.
Dr. Steven H. Stein M.D.
Executive Vice President & Chief Medical Officer
Mr. Michael James Morrissey
Executive Vice President & Head of Global Technical Operations

How INCY did perform over past 52-week?

INCY's closing price is 99.53% higher than its 52-week low of $53.56 where as its distance from 52-week high of $112.29 is -4.83%.

How many employees does INCY have?

Number of INCY employees currently stands at 2,617.

Link for INCY official website?

Official Website of INCY is: https://www.incyte.com

How do I contact INCY?

INCY could be contacted at phone 302 498 6700 and can also be accessed through its website. INCY operates from 1801 Augustine Cut-Off, Wilmington, DE 19803, United States.

How many shares of INCY are traded daily?

INCY stock volume for the day was 1.52M shares. The average number of INCY shares traded daily for last 3 months was 2.35M.

What is the market cap of INCY currently?

The market value of INCY currently stands at $20.98B with its latest stock price at $106.87 and 196.32M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	2617
Beta	0.82
Sales or Revenue	$3.70B
5Y Sales Change%	0.865%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

INCY Company Profile and Key Details

Incyte

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook